Development of an in vivo gene mutation assay using the endogenousPig-Agene: I. Flow cytometric detection of CD59-negative peripheral red blood cells and CD48-negative spleen T-cells from the rat

2008 ◽  
Vol 49 (8) ◽  
pp. 614-621 ◽  
Author(s):  
Daishiro Miura ◽  
Vasily N. Dobrovolsky ◽  
Yoshinori Kasahara ◽  
Yasuhiro Katsuura ◽  
Robert H. Heflich
Keyword(s):  
T Cells ◽  
Red Blood Cells ◽  
Gene Mutation ◽  
Blood Cells ◽  
Flow Cytometric ◽  
Mutation Assay ◽  
Gene Mutation Assay

Development of an in vivo gene mutation assay using the endogenousPig-Agene: II. Selection ofPig-Amutant rat spleen T-cells with proaerolysin and sequencingPig-AcDNA from the mutants

2008 ◽  
Vol 49 (8) ◽  
pp. 622-630 ◽  
Author(s):  
Daishiro Miura ◽  
Vasily N. Dobrovolsky ◽  
Roberta A. Mittelstaedt ◽  
Yoshinori Kasahara ◽  
Yasuhiro Katsuura ◽  
...  
Keyword(s):  
T Cells ◽  
Gene Mutation ◽  
Mutation Assay ◽  
Gene Mutation Assay

scholarly journals Effective use of the Pig-a gene mutation assay for mutagenicity screening: measuring CD59-deficient red blood cells in rats treated with genotoxic chemicals

2012 ◽  
Vol 37 (5) ◽  
pp. 943-955 ◽  
Author(s):  
Takafumi Kimoto ◽  
Satsuki Chikura ◽  
Kumiko Suzuki-Okada ◽  
Xiao-mei Kobayashi ◽  
Yasuhiro Itano ◽  
...  
Keyword(s):  
Red Blood Cells ◽  
Gene Mutation ◽  
Blood Cells ◽  
Effective Use ◽  
Mutation Assay ◽  
Genotoxic Chemicals ◽  
Gene Mutation Assay

scholarly journals The in vivo Pig-a gene mutation assay is applied to study the genotoxicity of procarbazine hydrochloride in Sprague-Dawley rats

2016 ◽  
Vol 3 (4) ◽  
pp. 167-175 ◽  
Author(s):  
Jiang Pu ◽  
Yuanyuan Deng ◽  
Xiaoyan Tan ◽  
Gaofeng Chen ◽  
Cong Zhu ◽  
...  
Keyword(s):  
Gene Mutation ◽  
Sprague Dawley ◽  
Sprague Dawley Rats ◽  
Mutation Assay ◽  
Gene Mutation Assay

Application of the in vivo Pig-a gene mutation assay to test the potential genotoxicity of p-phenylenediamine

2019 ◽  
Vol 123 ◽  
pp. 424-430 ◽  
Author(s):  
Meirong Qin ◽  
Runhua Chen ◽  
Zeyu Huang ◽  
Jinping Wang ◽  
Suowen Xu ◽  
...  
Keyword(s):  
Gene Mutation ◽  
Mutation Assay ◽  
Gene Mutation Assay

scholarly journals Fullerene (C60) Is Negative in the In Vivo Pig-A Gene Mutation Assay

2011 ◽  
Vol 33 (1) ◽  
pp. 27-31 ◽  
Author(s):  
Katsuyoshi Horibata ◽  
Akiko Ukai ◽  
Naoki Koyama ◽  
Atsuya Takagi ◽  
Jun Kanno ◽  
...  
Keyword(s):  
Gene Mutation ◽  
Fullerene C60 ◽  
Mutation Assay ◽  
Gene Mutation Assay

scholarly journals Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Xuqing Zhang ◽  
Mengyao Luo ◽  
Shamael R. Dastagir ◽  
Mellissa Nixon ◽  
Annie Khamhoung ◽  
...  
Keyword(s):  
T Cells ◽  
T Cell ◽  
Red Blood Cells ◽  
Blood Cells ◽  
Checkpoint Inhibitors ◽  
Critical Role ◽  
Cellular Immunotherapy ◽  
Tumor Control

AbstractCheckpoint inhibitors and T-cell therapies have highlighted the critical role of T cells in anti-cancer immunity. However, limitations associated with these treatments drive the need for alternative approaches. Here, we engineer red blood cells into artificial antigen-presenting cells (aAPCs) presenting a peptide bound to the major histocompatibility complex I, the costimulatory ligand 4-1BBL, and interleukin (IL)-12. This leads to robust, antigen-specific T-cell expansion, memory formation, additional immune activation, tumor control, and antigen spreading in tumor models in vivo. The presence of 4-1BBL and IL-12 induces minimal toxicities due to restriction to the vasculature and spleen. The allogeneic aAPC, RTX-321, comprised of human leukocyte antigen-A*02:01 presenting the human papilloma virus (HPV) peptide HPV16 E711-19, 4-1BBL, and IL-12 on the surface, activates HPV-specific T cells and promotes effector function in vitro. Thus, RTX-321 is a potential ‘off-the-shelf’ in vivo cellular immunotherapy for treating HPV + cancers, including cervical and head/neck cancers.

The in vivo pig-a gene mutation assay, a potential tool for regulatory safety assessment

2010 ◽  
Vol 51 (8-9) ◽  
pp. 825-835 ◽  
Author(s):  
Vasily N. Dobrovolsky ◽  
Daishiro Miura ◽  
Robert H. Heflich ◽  
Stephen D. Dertinger
Keyword(s):  
Gene Mutation ◽  
Safety Assessment ◽  
Mutation Assay ◽  
Gene Mutation Assay ◽  
Potential Tool

Studies of the Toxicological Potential of Capsinoids: V. Genotoxicity Studies of Dihydrocapsiate

2008 ◽  
Vol 27 (3_suppl) ◽  
pp. 59-72 ◽  
Author(s):  
Bruce K. Bernard ◽  
Eri Watanabe ◽  
Terutaka Kodama ◽  
Shoji Tsubuku ◽  
Akira Otabe ◽  
...  
Keyword(s):  
Gene Mutation ◽  
Chromosomal Aberration ◽  
Metabolic Activation ◽  
Transgenic Rats ◽  
Negative Results ◽  
Chromosomal Aberration Test ◽  
Mutation Assay ◽  
Gene Mutation Assay

A series of studies was performed to evaluate the safety of dihydrocapsiate (4-hydroxy-3-methoxybenzyl 8-methylnonanoate; CAS no. 205687-03-2). This study evaluated the potential genotoxicity of this compound using a variety of in vitro and in vivo test systems, including bacterial reverse mutation test, chromosomal aberration test, micronucleus test, gene mutation assay with transgenic rats, and single-cell gel (SCG) assay (Comet assay). In vitro tests (bacterial reverse mutation test and chromosomal aberration test) produced positive results in the absence of metabolic activation, but negative results in the presence of metabolic activation. The in vivo gene mutation assay (with transgenic rats) produced negative results, as did the in vivo mouse micronucleus assay, which failed to induce micronucleated polychromatic erythrocytes. Although the rat SCG assay produced statistically significant increases in the Olive tail moment and % tail DNA of the liver and intestine in the 2000 mg/kg group (compared with the negative-control group), a number of factors caused the authors to question the validity of these findings. Taken together, these results suggest that dihydrocapsiate has a low or extremely low likelihood of inducing genotoxicity.

Toxicology of Diethylene Glycol Butyl Ether 3. Genotoxicity Evaluation in an In Vitro Gene Mutation Assay and an In Vivo Cytogenetic Test

1993 ◽  
Vol 12 (2) ◽  
pp. 155-159 ◽  
Author(s):  
B. Bhaskar Gollapudi ◽  
V. A. Linscombe ◽  
M. L. Mcclintock ◽  
A. K. Sinha ◽  
C. R. Stack
Keyword(s):  
Bone Marrow ◽  
Gene Mutation ◽  
Micronucleus Test ◽  
Mouse Bone Marrow ◽  
Butyl Ether ◽  
Polychromatic Erythrocytes ◽  
Mutation Assay ◽  
Gene Mutation Assay

DGBE was evaluated in a forward gene mutation assay at the HGPRT locus of CHO cells in culture and in an in vivo mouse bone marrow micronucleus test for cytogenetic damage. DGBE did not elicit a positive response in the CHO/HGPRT assay when tested up to a maximum concentration of 5000 μg/ml with and without an external metabolic activation system (S-9). In the micronucleus test employing three post-treatment bone marrow sampling times (24, 48, and 72 hr), DGBE was ineffective in increasing the incidence of micronucleated polychromatic erythrocytes (MN-PCE) when tested in both sexes up to a maximum tolerated dose of 3300 mg/kg body weight. Thus, these data and those of others indicate a general lack of genotoxic potential for DGBE in short-term tests.

Sign in / Sign up

Export Citation Format

Share Document